Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (20529)	5/11/1998 9:39:00 PM
From: Henry Niman	Respond to of 32384

Greg, LGND has already addressed the sales force issue ( I think that they planned on having 12 sales people and a head in the US and an equal number in Europe for Panretin). I suspect that the same force will sell ONTAK and Targretin.

To: RXGOLF who wrote (20529)	5/11/1998 9:41:00 PM
From: squetch	Respond to of 32384

RXGOLF, I share your concern. Maybe we could guess by looking at the analyst's reports. I looked at AGPH when they ramped up to sell Viracept. It was cleared by the FDA in Mar 97. I looked at the 6 months prior and six months after to approval. I guessed they would have lots of manufacturing costs prior to launch. Not perfect, but SGA was ~40 million more in 4 quarters ended Sept 97 vs Sept 96. Seems like a big expense to me. In the past Henry said he thought LGND's cost would be much less. squetch